Preclinical Alzheimer disease: Brain oxidative stress, Aβ peptide and proteomics

Neurobiology of Disease

Volumn 39, Issue 2, 2010, Pages 221-228

  Aluise, Christopher D ^a,b   Robinson, Renã A Sowell ^a,b   Beckett, Tina L ^b   Murphy, M Paul ^b   Cai, Jian ^c   Pierce, William M ^c   Markesbery, William R ^b   Butterfield, D Allan ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

Amyloid beta; Brain; Inferior parietal lobule (IPL); Oxidative stress; Preclinical Alzheimer; Proteomics

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42];

AGED; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOCHEMISTRY; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARIETAL LOBE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CASE-CONTROL STUDIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PARIETAL LOBE; PEPTIDE FRAGMENTS; PROTEIN CARBONYLATION; PROTEOMICS; SPECTRUM ANALYSIS; TYROSINE;

EID: 77953690754     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.04.011     Document Type: Article

References (76)

1. Aksenov M.Y., Tucker H.M., Nair P., Aksenova M.V., Butterfield D.A., Estus S., Markesbery W.R. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J. Mol. Neurosci. 1998, 11:151-164.
2. Aluise C.D., Sowell R.A., Butterfield D.A. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim. Biophys. Acta 2008, 1782:549-558.
3. Bradley M.A., Markesbery W.R., Lovell M.A. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer's disease (PCAD). Free Radic. Biol. Med. 2010, 48:1570-1576.
4. Butterfield D.A., Stadtman E.R. Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol. 1997, 2:161-191.
5. Butterfield D.A., Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis. 2007, 12:61-72.
6. Butterfield D.A., Sultana R. Redox proteomics: understanding oxidative stress in the progression of age-related neurodegenerative disorders. Expert Rev. Proteomics 2008, 5:157-160.
7. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7:548-554.
8. Butterfield D.A., Poon H.F., St Clair D., Keller J.N., Pierce W.M., Klein J.B., Markesbery W.R. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol. Dis. 2006, 22:223-232.
9. Butterfield D.A., Reed T.T., Perluigi M., De Marco C., Coccia R., Keller J.N., Markesbery W.R., Sultana R. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 2007, 1148:243-248.
10. Butterfield D.A., Galvan V., Lange M.B., et al. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic. Biol. Med. 2010, 48:136-144.
11. Castano E.M., Roher A.E., Esh C.L., Kokjohn T.A., Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res. 2006, 28:155-163.
12. Cataldo A.M., Nixon R.A. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:3861-3865.
13. Cataldo A.M., Barnett J.L., Berman S.A., Li J., Quarless S., Bursztajn S., Lippa C., Nixon R.A. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron 1995, 14:671-680.
14. Das P., Howard V., Loosbrock N., Dickson D., Murphy M.P., Golde T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci. 2003, 23:8532-8538.
15. Dreyer R.N., Bausch K.M., Fracasso P., et al. Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer's disease mutation. Eur. J. Biochem. 1994, 224:265-271.
16. Elder G.A., Friedrich V.L., Bosco P., Kang C., Gourov A., Tu P.H., Lee V.M., Lazzarini R.A. Absence of the mid-sized neurofilament subunit decreases axonal calibers, levels of light neurofilament (NF-L), and neurofilament content. J. Cell Biol. 1998, 141:727-739.
17. Evin G., Cappai R., Li Q.X., Culvenor J.G., Small D.H., Beyreuther K., Masters C.L. Candidate gamma-secretases in the generation of the carboxyl terminus of the Alzheimer's disease beta A4 amyloid: possible involvement of cathepsin D. Biochemistry 1995, 34:14185-14192.
18. Fukui H., Diaz F., Garcia S., Moraes C.T. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14163-14168.
19. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M., Yankner B.A. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 1998, 4:827-831.
20. Giuffrida M.L., Caraci F., Pignataro B., et al. Beta-amyloid monomers are neuroprotective. J. Neurosci. 2009, 29:10582-10587.
21. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
22. Haass C., Schlossmacher M.G., Hung A.Y., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325.
23. Higaki J., Catalano R., Guzzetta A.W., Quon D., Nave J.F., Tarnus C., D'Orchymont H., Cordell B. Processing of beta-amyloid precursor protein by cathepsin D. J. Biol. Chem. 1996, 271:31885-31893.
24. Howlett D.R., Bowler K., Soden P.E., et al. Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease. Histol. Histopathol. 2008, 23:67-76.
25. Hsu D.K., Yang R.Y., Liu F.T. Galectins in apoptosis. Methods Enzymol. 2006, 417:256-273.
26. Iacono D., Markesbery W.R., Gross M., Pletnikova O., Rudow G., Zandi P., Troncoso J.C. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 2009, 73:665-673.
27. Kinoshita A., Kinoshita M., Akiyama H., Tomimoto H., Akiguchi I., Kumar S., Noda M., Kimura J. Identification of septins in neurofibrillary tangles in Alzheimer's disease. Am. J. Pathol. 1998, 153:1551-1560.
28. Kish S.J., Bergeron C., Rajput A., Dozic S., Mastrogiacomo F., Chang L.J., Wilson J.M., DiStefano L.M., Nobrega J.N. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 1992, 59:776-779.
29. Kittur S., Hoh J., Endo H., Tourtellotte W., Weeks B.S., Markesbery W., Adler W. Cytoskeletal neurofilament gene expression in brain tissue from Alzheimer's disease patients. I. Decrease in NF-L and NF-M message. J. Geriatr. Psychiatry Neurol. 1994, 7:153-158.
30. Kohnken R.E., Ladror U.S., Wang G.T., Holzman T.F., Miller B.E., Krafft G.A. Cathepsin D from Alzheimer's-diseased and normal brains. Exp. Neurol. 1995, 133:105-112.
31. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
32. LeVine H. Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal. Biochem. 2004, 335:81-90.
33. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
34. Li X., Serwanski D.R., Miralles C.P., Nagata K., De Blas A.L. Septin 11 is present in GABAergic synapses and plays a functional role in the cytoarchitecture of neurons and GABAergic synaptic connectivity. J. Biol. Chem. 2009, 284:17253-17265.
35. Lim J., Balastik M., Lee T.H., et al. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J. Clin. Invest. 2008, 118:1877-1889.
36. Liu F.T. Galectins: novel anti-inflammatory drug targets. Expert. Opin. Ther. Targets 2002, 6:461-468.
37. Lovell M.A., Markesbery W.R. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J. Neurosci. Res. 2007, 85:3036-3040.
38. Lu K.P., Hanes S.D., Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996, 380:544-547.
39. Lyubartseva G., Smith J.L., Markesbery W.R., Lovell M.A. Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol. 2009.
40. Markesbery W.R. The role of oxidative stress in Alzheimer disease. Arch. Neurol. 1999, 56:1449-1452.
41. Markesbery W.R., Lovell M.A. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch. Neurol. 2007, 64:954-956.
42. Markesbery W.R., Kryscio R.J., Lovell M.A., Morrow J.D. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 2005, 58:730-735.
43. McGowan E., Pickford F., Kim J., et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005, 47:191-199.
44. Murphy M.P., Beckett T.L., Ding Q., Patel E., Markesbery W.R., St Clair D.K., LeVine H., Keller J.N. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol. Dis. 2007, 27:301-311.
45. Mutisya E.M., Bowling A.C., Beal M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 1994, 63:2179-2184.
46. O'Brien R.J., Resnick S.M., Zonderman A.B., et al. Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J. Alzheimers. Dis. 2009, 18:665-675.
47. Opii W.O., Joshi G., Head E., Milgram N.W., Muggenburg B.A., Klein J.B., Pierce W.M., Cotman C.W., Butterfield D.A. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol. Aging 2008, 29:51-70.
48. Pastorino L., Sun A., Lu P.J., et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006, 440:528-534.
49. Petrie E.C., Cross D.J., Galasko D., Schellenberg G.D., Raskind M.A., Peskind E.R., Minoshima S. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch. Neurol. 2009, 66:632-637.
50. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991, 563:311-314.
51. Price J.L., McKeel D.W., Buckles V.D., et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 2009, 30:1026-1036.
52. Rabinovich G.A., Alonso C.R., Sotomayor C.E., Durand S., Bocco J.L., Riera C.M. Molecular mechanisms implicated in galectin-1-induced apoptosis: activation of the AP-1 transcription factor and downregulation of Bcl-2. Cell Death Differ. 2000, 7:747-753.
53. Rabinovich G.A., Ramhorst R.E., Rubinstein N., Corigliano A., Daroqui M.C., Kier-Joffe E.B., Fainboim L. Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms. Cell Death Differ. 2002, 9:661-670.
54. Reed T., Perluigi M., Sultana R., Pierce W.M., Klein J.B., Turner D.M., Coccia R., Markesbery W.R., Butterfield D.A. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 2008, 30:107-120.
55. Reed T.T., Pierce W.M., Turner D.M., Markesbery W.R., Butterfield D.A. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J. Cell. Mol. Med. 2008.
56. Reed T.T., Owen J., Pierce W.M., Sebastian A., Sullivan P.G., Butterfield D.A. Proteomic identification of nitrated brain proteins in traumatic brain-injured rats treated postinjury with gamma-glutamylcysteine ethyl ester: insights into the role of elevation of glutathione as a potential therapeutic strategy for traumatic brain injury. J. Neurosci. Res. 2009, 87:408-417.
57. Rosengren L.E., Karlsson J.E., Sjogren M., Blennow K., Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999, 52:1090-1093.
58. Saftig P., Peters C., von Figura K., Craessaerts K., Van Leuven F., De Strooper B. Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D. J. Biol. Chem. 1996, 271:27241-27244.
59. Schmidt M.L., Lee V.M., Trojanowski J.Q. Comparative epitope analysis of neuronal cytoskeletal proteins in Alzheimer's disease senile plaque neurites and neuropil threads. Lab. Invest. 1991, 64:352-357.
60. Schutkowski M., Bernhardt A., Zhou X.Z., Shen M., Reimer U., Rahfeld J.U., Lu K.P., Fischer G. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. Biochemistry 1998, 37:5566-5575.
61. Seubert P., Vigo-Pelfrey C., Esch F., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992, 359:325-327.
62. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27:2866-2875.
63. Shankar G.M., Li S., Mehta T.H., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
64. Shen M., Stukenberg P.T., Kirschner M.W., Lu K.P. The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev. 1998, 12:706-720.
65. Shoji M., Golde T.E., Ghiso J., et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992, 258:126-129.
66. Smith M.A., Perry G. Alzheimer disease: protein-protein interaction and oxidative stress. Bol. Estud. Med. Biol. 1996, 44:5-10.
67. Sultana R., Boyd-Kimball D., Poon H.F., et al. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol. Aging 2006, 27:918-925.
68. Sultana R., Boyd-Kimball D., Cai J., Pierce W.M., Klein J.B., Merchant M., Butterfield D.A. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J. Alzheimers Dis. 2007, 11:153-164.
69. Sultana R., Reed T., Perluigi M., Coccia R., Pierce W.M., Butterfield D.A. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J. Cell. Mol. Med. 2007, 11:839-851.
70. Sultana R., Piroddi M., Galli F., Butterfield D.A. Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem. Res. 2008, 33:2540-2546.
71. Sultana R., Perluigi M., Butterfield D.A. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol. 2009, 118:131-150.
72. Sultana R., Perluigi M., Newman S.F., Pierce W.M., Cini C., Coccia R., Butterfield A. Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. Antioxid. Redox. Signal. 2010, 12:327-336.
73. Thongboonkerd V., Luengpailin J., Cao J., Pierce W.M., Cai J., Klein J.B., Doyle R.J. Fluoride exposure attenuates expression of Streptococcus pyogenes virulence factors. J. Biol. Chem. 2002, 277:16599-16605.
74. Vespa G.N., Lewis L.A., Kozak K.R., Moran M., Nguyen J.T., Baum L.G., Miceli M.C. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J. Immunol. 1999, 162:799-806.
75. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
76. West M.J., Kawas C.H., Stewart W.F., Rudow G.L., Troncoso J.C. Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol. Aging 2004, 25:1205-1212.